Esperion Therapeutics, Inc.
ESPREsperion Therapeutics, Inc.
NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$2.62
+0.01(0.19%)
52W $0.73 – $4.08
AI-generated
Esperion Therapeutics, Inc.
Revenue breakdown: Collaboration Revenue (44.6%), Royalty Revenue From DSE And Sale Of Bulk Tablets And Milestones Received (29.1%), Product (26.3%).
$544MMkt Cap
$354MRev TTM
-$20MNI TTM
-27.3xP/E TTM
Latest Earnings
10-K
FY FY2025Mar 9, 2026Esperion Therapeutics, Inc. reported total revenues of $403.1 million for fiscal year 2025, generating a gross profit of $273.9 million (calculated from total revenues of $403.1M minus cost of goods sold of $129.2M). The company achieved income from operations of $60.3 million, but significant interest expense of $84.6M resulted in a net loss of $22.7 million. The balance sheet shows...
What Changed Recently
Fundamentals
How The Business Makes Money
Revenue by Segment
Collaboration Revenue44.6%($601M)
Royalty Revenue From DSE And Sale Of Bulk Tablets And Milestones Received29.1%($391M)
Product26.3%($354M)
Analyst View
Company Profile
CIK0001434868
ISINUS29664W1053
CUSIP29664W105
Phone734 887 3903
Address3891 Ranchero Drive, Ann Arbor, MI, 48108, US
SEC EDGAR